Tony Kennedy

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.

Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden.

Merifin Europe SA (Merifin Capital) is an independent private investment group which was established in 1989. From its offices in Brussels, Geneva, New York and London, Merifin Capital invests in traditional and alternative asset classes.

Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto.

Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million.

Carmel Pharma AB manufactures PhaSeal System, a clinically proven closed-system drug transfer device (CSTD) for the safe handling of hazardous drugs. The company expanded its safe handling initiatives to the U.S. market with the formation of Carmel Pharma, Inc., which operates a corporate office and distribution facility out of Columbus, OH. Carmel Pharma AB was founded in 1994 and is headquartered in Gothenburg, Sweden.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

New York Philharmonic provides live theatrical presentations. The company was founded in 1842 and is headquartered in New York, NY.

3i Nordic Plc (3i Nordic) is the Swedish venture capital subsidiary of 3i Group Plc (LSE: III) in Great Britain. Formerly known as Atle AB, founded in 1993, the firm was acquired by 3i in 2001 and renamed 3i Nordic. Located in Stockholm, 3i Nordic utilizes specialized 3i Group resources to provide financial experience, sector knowledge, company management practice and access to 3i's network of international contacts to investee companies. 3i Nordic is part of the 3i Nordic investment team which includes investment professionals from the Helsinki and Copenhagen offices.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.

Industrie Saleri Italo SpA engages in the manufacture of water pumps and cooling systems for the automotive industry. Its products include mechanical water pumps, adjustable water pumps, water pumps with assembles modules, and electric water pumps. The company was founded in 1942 and is headquartered in Lumezzane, Italy.

Novo Nordisk Ltd. engages in the sale and marketing of pharmaceutical products for the treatment of chronic conditions in the United Kingdom. It offers medicines for the treatment of diabetes, and hemophilia and bleeding disorders, as well as for growth hormone therapy and hormone replacement therapy. The company is headquartered in Crawley, the United Kingdom.

Global Medical Investments GMI AB establishes and operates cancer centers in developing countries. It engages in the development and support of cancer management programs and cancer treatment clinics. The firm is an investment and project development company. It also secures contracts with health insurance companies and healthcare providers for private and state-run companies and government insurance agencies. The company was founded by Bror Thomas Pollare on July 24, 2009 and is headquartered in Solna, Sweden.

Bazando SAS operates as a platform for online shopping. It allows users to browse through outsourced and crowd sourced brands and offers products at discounted prices. The firm's products include clothing, shoes, and accessories for women, men, and children. It also sells miscellaneous items for the home, such as pillows, chairs, decorations, and gadgets. The company was founded by Olivier Cotinat, Nicolas Baudran, and Jerome Pellegrin in 2007 and is headquartered in Colombelles, France.

NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.

ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

A3P Biomedical AB is a Swedish company that aims to improve the precision in prostate cancer diagnostics and treatment. A3P Biomedical is headquartered in Sweden and has subsidiaries in the country. The private company's lead product is Stockholm3, a blood test for early detection of aggressive prostate cancer. The test has been developed by scientists at Institutet and validated in clinical studies involving more than 80,000 men. A total of SEK 750 million has been invested in clinical research, product development, and market validation activities. The company sells Stockholm3 to healthcare providers through direct sales and distributors.

VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland.